Selective killing and diagnosis of p53+ neoplastic cells
AssigneeOnyx Pharmaceuticals, Inc.
InventorsAdam Sampson-Johannes, David Kirn
Life of this patent
Estimating the term…
Loading patent…
AssigneeOnyx Pharmaceuticals, Inc.
InventorsAdam Sampson-Johannes, David Kirn
Estimating the term…
Methods and compositions for treating and diagnosing neoplastic disease using viruses are provided. Preferably, mutant adenovirus lacking viral proteins which bind and/or inactivate p53 are administered to a patient having a neoplasm which comprises cells exhibiting p53 and lacking, or substantially devoid of mismatch repair activity. The mutant virus is able to substantially produce a replication phenotype in such neoplastic cells but is substantially unable to produce a replication phenotype in non-replicating, non-neoplastic cells having essentially normal p53 function. The preferential generation of a replication phenotype in neoplastic cells results in a preferential killing of the neoplastic cells, either directly or by expression of a cytotoxic gene in cells expressing a viral replication phenotype.
A method for ablating neoplastic cells in a cell population, comprising the steps of:
A method for diagnosing the susceptibility of a patient's tumor to treatment with recombinant adenovirus, said tumor comprising neoplastic cells that exhibit the tumor suppressor p53, and said recombinant adenovirus having the property of lacking an expressed viral oncoprotein capable of binding a functional p53 tumor suppressor gene product;
Dependencies are inferred from the claim text.